CMMB Shared Facility Director
Office: BSF 134
Lab: BSF 119, 121, 123, 125
Ph.D., University of Florida, 2001
Mass spectrometry (MS)-based proteomics has become a powerful, unbiased approach to understand the complex molecular mechanisms underlying fundamental biological processes as well as mechanisms associated with the development and progression of human disease. This approach is an integral component of our research program, where we are investigating the impact of epigenetic changes that occur in the brain and liver after alcohol exposure. Specifically, we utilize MS to identify and quantify changes in alcohol-induced histone modifications as well as differential protein expression on a global scale in cell culture and animal models of acute and chronic alcohol exposure. In conjunction with bioinformatics, MS-based proteomic data can be used to not only determine novel proteins and/or pathways that are affected due to a specific physiological or pathophysiological state, but can also predict the activity of potential upstream regulators (e.g., transcription factors) and downstream functional outcomes. The results from proteomic and bioinformatic analysis (as well as complementary approaches such as RNA-Seq, ChIP-Seq and ATAC-Seq) can provide a detailed mechanistic framework for the development of targeted hypotheses, which currently include the role of epigenetic writers/erasers in modulating the histone code that ultimately give rise to cellular changes related to disease phenotype.